cyrilzakka/clinical-trials huggingface dataset:
Effects of Age and Infertility on Ovarian Granulosa Cell Function

Infertility is a life changing disorder, affecting 1 in 7 couples within the UK. Treatment options pose a significant cost burden to both the NHS and patient when NHS-funded treatment options are exhausted. This highlights the need for refinements in clinical management strategies for this patient group. Although there have been advancements in assisted reproductive technologies, the success rates of techniques such as in vitro fertilization (IVF) remain low. Surprisingly, the IVF hormonal regimens used by most assisted conception units fail to take account of patient age, ovarian reserve or cause of infertility when deciding on treatment regimen, with a 'one size fits all' approach to treatment. The investigators propose that age and cause of infertility modify the functions and environment provided by the cells (granulosa cells) that support egg (oocyte) growth and development and understanding these changes will allow for a more personalised approach to IVF treatment regimens. The aim of this study therefore is to recruit female patients undergoing IVF with different causes of infertility and age, and harvest granulosa cells from remaining material (follicular aspirates) generated at the time of egg retrieval. Granulosa cells will be cultured in vitro and cellular functions assessed. The investigators will also recruit female patients with normal fertility undergoing IVF procedure due to other reasons (i.e. egg freezing, diagnostics of genetic diseases on embryos).


Eligibility Criteria:
Inclusion Criteria:

* Any woman that is:
* fluent in English,
* capable of giving consent,
* reproductive age (between the ages of 18-45),
* is HIV and Hep A and Hep B negative.
* undergoing IVF treatment for one of the following reasons:

  1. unexplained infertility
  2. tubal disease
  3. egg freezing
  4. polycystic ovarian syndrome
  5. ovulatory disorders
  6. endometriosis
  7. male factor infertility
  8. any other cause of infertility such as fibroids.

Exclusion Criteria:

* Adults unable to consent for themselves,
* Non-fluent English speakers, unless in clinic translators are available
* Aged less than 18
* Is HIV or Hep A or B positive, or has not undergone screening.
Plasmapheresis Versus Plasma Infusion from Young APOE3 Homozygotes Into MCI APOE4 Homozygotes to Slow Disease Progression

Determine safety of plasma infusion or exchange in APOE 44 patients.


Eligibility Criteria:
Inclusion criteria

* Patient age 50 to 75.
* APOE 44 homozygote.
* Meets the Petersen criteria for MCI (41).
* Clinical Dementia Rating (CDR) of 0.5 and Mini Mental Status Examination (MMSE) of 24 to 30 inclusive.
* Has an informant who the investigator judges has sufficient patient contact to provide accurate information.
* Stable depression and or anxiety.
* Stable psychoactive medication for 6 weeks.

Exclusion criteria

* History of severe reaction to plasma or plasma derived products which include but not limited to severe allergic reaction, anaphylactic reaction and transfusion related acute lung injury (TRALI).
* Patients who do not want to receive blood transfusion for religious or cultural reasons such as Jehovah Witness Faith.
* Has a medical condition that would interfere with participation such as congestive heart failure (New York Heart Association Class III or IV), unstable angina, moderate to severe renal impairment, liver failure, and poorly controlled diabetes.
* History of autoimmune disease considered clinically significant or requiring chronic steroid or immune suppression medication.
* History of being HIV +.
* History of +VE test result indicating active hepatitis C or B (defined as both hepatitis B surface antigen and hepatitis core antibody +VE).
* Uncontrolled hypertension as defined by systolic/diastolic BP three times more than 165/100.
* No venous access for plasma exchange therapy.
* Any neurological condition that could be contributing to cognitive decline such as Lewy body disease, front temporal dementia, strokes or other cerebrovascular disease, head trauma, substance abuse, multiple sclerosis, Vitamin B12 deficiency, thyroid deficiency.
* Epileptic seizures within 10 years of screening.
* Cancer diagnosis (other than non-melanoma skin cancer) in the last 5 years.
* More than 1 subcortical stroke or more than 1 cortical stroke.
* Unable to have an MRI.
* MRI showing acute or subacute hemorrhage, evidence of normal pressure hydrocephalus, hemispheric infarcts, glioma or other brain tumor that could contribute to cognitive decline.
* Unstable psychiatric condition.
* On another experimental treatment study or has been on one in the last 3 months.
* If a patient consents to lumbar puncture (LP), they will be excluded from LP if any contraindication to having an LP is present. Examples are platelet count\<100,000, spine deformity or contraindication to come off blood thinner for the LP. Patients may still participate in the rest of the study without having and LP.
* Any unspecified reason that the investigator finds the patient unsuitable to take part.
Increasing Breast Cancer Screening in Chinese Immigrants

The long-term goal of this research is to increase breast cancer screening rates in NYC Chinese immigrants. The researchers plan to accomplish this objective by developing and testing a culturally- and linguistically-adapted Witness Project program for Chinese immigrants. To inform the intervention development, the study team will identify barriers and facilitators to breast cancer screening in Chinese immigrants through individual qualitative interviews.

A total of 156 participants will be recruited during the entire study.

In Aim 1 which started in July 2021, 60 women were recruited for in-depth interviews to assess their breast cancer knowledge, perceived barriers and benefits/risks to completing mammography, perceived susceptibility to breast cancer, fatalism, screening intention, acculturation, language preference, and health literacy.

In Aim 2, 96 women will be recruited to participate in the pilot testing of the intervention. Recruitment will take place at community sites that serve Chinese immigrants in New York City. Enrollment for Aim 2 is anticipated to start in March of 2022.


Eligibility Criteria:
Inclusion Criteria:

* ≥ 40 years of age
* female
* born in China
* read and speak Cantonese, Mandarin, or English

Exclusion Criteria:

- none
Personal FET in RIF Patients According to Histological Dating of Endometrial of Natural/ Hormone Replacement Cycle

At present, the evaluation criterion of endometrial receptivity is controversial. The development of a molecular diagnostic tool, the endometrial receptivity array (ERA) for diagnosis of endometrial receptivity . But use of this test in patients with RIF has shown that the window of implantation (WOI) is displaced in only a quarter of these patients and use of a personalized embryo transfer (pET) on the day designated by ERA improves reproductive performance with higher cost .what is known to the others'population? The morphological changes observed on histology for each specific day after ovulation were described by Noyes and his colleagues in 1950 . An endometrial biopsy that shows a difference of more than 2 days between the histologic dating and actual day after ovulation is considered to be ''out of phase''. But such pET studies according to the Noyes criterion are lacking . The aim of this study is to explore the Personal frozen-thawed embryo transfer in unexplained RIF patients according to the blinded histological dating of endometrial biopsies .


Eligibility Criteria:
Inclusion Criteria:

The inclusion criteria for RIF group were:

•unexplained repeated implantation failure (RIF) which is defined as the absence of a gestational sac on ultrasound at 5 or more weeks after embryo transfer (ET) after 3 embryo transfers with high quality embryos or after the transfer of ≥10 embryos in multiple transfers.

The inclusion criteria for control group were:

* age \<35 years;
* regular menstrual cycles of 24-35 days;
* baseline follicle- stimulating hormone (FSH) \< 9.0 IU/L;
* endometrial thickness ≥8.0 mm on the day of hCG administration.

Exclusion Criteria:

* uterine abnormalities (double uterus, bicornuate uterus, unicornuate uterus);
* intrauterine adhesions（moderate - severe）, endometriosis, adenomyosis, untreated hydrosalpinx, uterine fibroids (submucosal fibroids, nonmucosal fibroids \>4.0 cm and/or endometrial pressure)
* history of adverse pregnancy (including spontaneous abortion, stillbirth, and fetal malformation).
The Effects of Brown Rice Compared to White Rice on Postprandial Changes in IL-6 and MDA Levels in Sedentary Workers

The goal of this clinical trial is to learn if brown rice and white rice affect oxidative stress and inflammation in office workers who don't exercise much. The main question it aims to answer is:

Does eating brown rice change MDA and IL-6 levels differently than eating white rice in people who don't exercise much?

Participants will:

Be interviewed to collect personal data, medical history, lifestyle habits, and dietary patterns.

Be measured to calculate Body Mass Index (BMI). Be interviewed to complete a questionnaire to assess their physical activity level in the past week.

Be interviewed to record all food and beverages consumed in the past 24 hours. Blood samples will be drawn twice, before and after consuming the research meal.

Be provided with a research meal consisting of rice (either brown or white), scrambled eggs, and tofu stew that must be finished within 15 to 20 minutes.


Eligibility Criteria:
Inclusion Criteria:

* healthy administrative employees,
* age 21-59 years,
* normal body mass index (18.5-22.9 kg/m2),
* low physical activity (≤600 METs minutes/week),
* assign for informed consent

Exclusion Criteria:

* being pregnant/breastfed/menopause,
* consumption of herbal medicines and/or supplements within 24 hours before data collection,
* having history of DM, CVD, cancer, and autoimmune disease,
* being vegan,
* smoking/alcohol drinking,
* allergic to research food's ingredients
Teach-back Method on Patient Satisfaction and Adherence to Wound Care Regimen

The purpose of this study is to examine a different way to educate patients about taking care of their wound and see how this method affects patient satisfaction, compliance to the wound care regimen, and patient experience.

The teach-back method is delivered using the ask-tell-ask method. Investigators will ask the patient about their knowledge of wound care healing, provide the patient educational component, then ask the patient to repeat what was said. If the answer is wrong or incomplete, the researcher will go over the information again with the patient to clear up any misunderstandings.

Patients undergoing Mohs Micrographic surgery for skin cancers on the lower extremities for the first time that are left to heal by secondary intention are randomized either to receive a scripted teach-back session or a standard of care wound care education. This study wishes to compare wound care adherence, patient experience, wound complications, and the number of phone calls made by patients to the office between the two cohorts

primary objective is to determine whether study participants who have received the teach-back method have an increase wound care adherence at one week post-operatively, compared to those who received the standard of care.

To characterize differences in the patient experience between the two interventional groups 2 weeks after surgery.

To determine whether the number of phone calls made post-operatively by patients will decrease in a 2 week follow-up time period.

To characterize the differences in patient wound care adherence at 2 weeks after surgery.

To determine whether there is a difference in complication incidence post-operatively

Eligibility Criteria:
Inclusion Criteria:

* Presenting to outpatient Mohs clinic at University Department of Dermatology, Two Chagrin Highlands for the first time
* Have excision(s) from Mohs Micrographic Surgery on the lower extremities that are left to heal by secondary intention
* English-speaking

Exclusion Criteria:

* Non-English speaking
* A clinical diagnosis of mental, learning, and visual disabilities
* A clinical diagnosis of dementia
* Those who have received Mohs Micrographic Surgery before regardless of area
Language Matters: Exploring the Impact of Language Concordance on Fertility Treatment Progression

Currently, patients presenting to the Fertility and Reproductive Medicine Center meet with an English-speaking provider and communicate through an interpreter, as none of the physicians speak Spanish. However, this study PI is a native Spanish speaker and certified bilingual clinician. Thus, this study is looking to evaluate whether or not the use of an interpreter delays completion of testing and initiation of fertility treatment. The medically indicated testing, procedures, and course of treatment will not be altered as a result of participation in the study. Participants will be asked to complete a survey in their preferred language to gauge satisfaction and communication efficacy.

This proposed study is significant as it seeks to address a critical gap in the understanding of how language concordance between healthcare providers and patients influences treatment outcomes in fertility care. With Spanish being the most commonly spoken non-English language in the U.S., evaluating the impact of Spanish language skills in medical care is both timely and essential. This research will shed light on whether Spanish-speaking patients experience better treatment progression and outcomes when cared for by language-concordant providers versus when interpreters are used in fertility care.

This prospective study will be conducted at Washington University's Fertility and Reproductive Medicine Center over a 12-month period. The investigators aim to enroll a total of 70 Spanish-speaking patients, based on previous patient trends at the Center 35 will be randomized to the intervention group (being evaluated and treated by a Spanish-speaking provider), and 35 will be randomized to standard of care (communicating with an English-speaking provider through an interpreter).


Eligibility Criteria:
Inclusion Criteria:

* Must be greater than 18 years old
* Preferred language must be Spanish speaking
* Must be seeking fertility treatment

Exclusion Criteria:

* Preferred language English
* Not currently seeking fertility care
* Less than 18 years old
The Effect of Treatment Zone Decentration on Axial Length Elongation After Orthokeratology

Orthokeratology lens is an effective method for myopia control. This study analyzed the effects of treatment zone decentration on axial length elongation in adolescents with orthokeratology lens.

Orthokeratology lens is an effective method for myopia control. This study aimed to investigate the effects of treatment zone decentration on axial length elongation in adolescents with orthokeratology lens in 1 year. Other factors that may affect axial growth were also analyzed.

Eligibility Criteria:
Inclusion Criteria:

* age from 8 to 15years
* spherical equivalent(SE) was range from -1.00D to -5.00D
* conform to the standard of wearing orthokeratology lens

Exclusion Criteria:

* ocular diseases and systemic diseases
* stop wearing for ≥7 days for any reason during the follow-up period
* keratoconjunctival complications, glare, diplopia, or any other symptoms during follow-up
A Double-blind, Placebo-controlled Study of Antidepressant Augmentation With Agomelatine

The purpose of this study was to investigate the efficacy and safety of antidepressant augmentation with agomelatine in the treatment of patients with depression who did not demonstrate satisfying response to selective serotonin reuptake inhibitor (SSRI) and serotonin-noradrenaline reuptake inhibitor (SNRI) during their early phase of treatment; this study also aims to explore the effects of augmenting antidepressant treatment with agomelatine on various aspects, including sleep quality, quality of life, social functioning, and cognitive function in patients with MDD.


Eligibility Criteria:
1. Age between 18 and 60 years.
2. Meeting the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-V) criteria for a current major depressive episode.
3. Demonstrating an inadequate response to antidepressant treatment lasting at least 2 weeks, at the minimum effective dose for antidepressants. Inadequate response is defined as a \< 20% change in the Hamilton Depression Rating Scale-17 (HAMD-17) score or as per patients' self-report in the antidepressant treatment questionnaire. Minimum effective doses for some commonly used classes of antidepressants include:

   * Sertraline: \>50mg
   * Fluoxetine: \>20 mg
   * Citalopram: \>20 mg
   * Escitalopram: \>10mg
   * Venlafaxine: \>75 mg
   * Duloxetine: \>50 mg
4. HAMD-17≥17; Clinical Global Impression-Severity (CGI-S) score ≥4.
5. Education level of at least 6 years, with the ability to independently complete all scales and assessments.
6. Agreement from primary healthcare providers and patients to maintain current antidepressant treatment while adding agomelatine.

\*\*Exclusion Criteria:\*\*

1. Meeting criteria for other psychiatric disorders according to DSM-IV (except generalized anxiety disorder), such as schizophrenia, bipolar disorder, or mental disorders related to alcohol and drug dependence.
2. Current or previous history of brain organic diseases or loss of consciousness for more than 5 minutes.
3. Current or previous history of major physical diseases (including rheumatic immune system diseases, endocrine and metabolic diseases, nervous system diseases, etc.).
4. Current serious suicidal ideation or suicide attempt.
5. Pregnancy or lactation in women.
6. Color blindness (which would hinder neurocognitive testing).
7. Use of anticoagulants (e.g., heparin, warfarin), glucocorticoids, or treatment for thyroid diseases in the past 3 months.
8. Having received any neurocognitive assessment similar to this study in the past 12 months.
9. Positive urine drug screening results or abnormal thyroid function test.
10. Liver function tests showing transaminase (ALT and AST) levels 2 times above the upper limit of the normal range.
11. Electrocardiogram examination revealing a QTc ≥ 430 ms in males or QTc ≥ 450 ms in females.
Validity, Reliability and Responsiveness of Pain Sensitization Questionnaire

The aim of this study was to translate the Pain Sensitivity Questionnaire, which was developed to determine the level of pain sensitivity of individuals, to Turkish and to evaluate the validity and reliability of the Turkish version of the scale on knee osteoarthritis patients, and as well as to perform cultural adaptation. Pain sensitivity assessment is used to predict treatment or surgical outcomes of individuals. IPain Sensitivity Questionnaire is a frequently used scale that correlates with experimental pain tests and is used in studies conducted in different patient groups. We believe that adding this scale to our language will contribute to other studies in this field.


Eligibility Criteria:
Inclusion Criteria:

* Not having oral or written communication problems in Turkish,
* Diagnosis of knee osteoarthritis after clinical examination and radiological imaging,
* Being 40 years or older,
* To have neurological competence and cognitive level to answer scale questions.

Exclusion Criteria:

* To have fibromyalgia syndrome or neurological disease that may affect pain sensitivity levels of individuals,
* To have undergone surgery involving the knee in the last 1 year,
* The presence of peripheral neuropathy and neuropathy is therefore to be taking medication.
Study of KHK7580 in Subjects With Secondary Hyperparathyroidism in Asia

The purpose of this study is to evaluate the efficacy and the safety of KHK7580 orally administered once daily for 52 weeks compared to cinacalcet hydrochloride as an active control in subjects with secondary hyperparathyroidism receiving hemodialysis in China, Korea, Hong Kong and Taiwan.


Eligibility Criteria:
Inclusion Criteria:

1. Personally submitted written voluntary informed consent to participate in the study
2. Aged ≧18 years at the time of consent
3. Stable chronic renal failure treated with hemodialysis 3 times weekly for at least 12 weeks before screening
4. Intact PTH level (centrally measured) of \>300 pg/mL at screening
5. Corrected serum Ca level (centrally measured) of ≧9.0 mg/dL at screening

Exclusion Criteria:

1. Treatment with cinacalcet hydrochloride within 2 weeks before screening
2. Change in dose or dosing regimen of an activated vitamin D drug or its derivative, phosphate binder, or Ca preparation within 2 weeks before screening; or start of treatment with such drugs within 2 weeks before screening
3. Change in prescribed conditions of dialysis (dialysate Ca concentration, prescribed dialysis time, and prescribed number of dialysis per week) within 2 weeks before screening
4. Treatment with bisphosphonates, denosumab or teriparatide within 24 weeks before screening
5. Parathyroidectomy and/or parathyroid intervention within 24 weeks before screening
6. Severe heart disease (e.g., ≧ Class Ⅲ per New York Heart Association classification)
7. Severe hepatic dysfunction (e.g., treatment with antiviral therapy)
8. Uncontrolled hypertension and/or diabetes
Budesonide Orodispersible Tablet vs. Placebo in Active Eosinophilic Esophagitis

The purpose of this study is to prove the superiority of a 6-weeks treatment with budesonide effervescent tablets versus placebo for the induction of clinico-pathological remission in patients with acute eosinophilic esophagitis.


Eligibility Criteria:
Inclusion Criteria:

* Signed informed consent,
* Male or female patients, 18 to 75 years of age,
* Confirmed clinico-pathological diagnosis of eosinophilic esophagitis (EoE) according to established diagnostic criteria
* Active symptomatic and histological EoE,
* A documented trial with proton pump inhibitors (PPIs) in order to rule out PPI-responsive esophageal eosinophilia,
* Negative pregnancy test in females of childbearing potential at baseline visit.

Exclusion Criteria:

* Clinical and endoscopic signs of gastroesophageal reflux disease (GERD),
* History of abnormal results in case of an optionally performed pH-monitoring of the distal esophagus,
* Patients with PPI-responsive esophageal eosinophilia
* Achalasia, scleroderma esophagus, or systemic sclerosis,
* Other clinically evident causes than EoE for esophageal eosinophilia,
* Any concomitant esophageal disease and relevant gastro-intestinal disease (celiac disease, inflammatory bowel disease, oropharyngeal or esophageal bacterial, viral, or fungal infection \[candida esophagitis\]),
* Any relevant systemic disease (e.g., AIDS, active tuberculosis),
* If careful medical monitoring is not ensured: cardiovascular disease, diabetes mellitus, osteoporosis, active peptic ulcer disease, glaucoma, cataract, or infection,
* Liver cirrhosis or portal hypertension,
* History of cancer in the last five years,
* History of esophageal surgery at any time or of esophageal dilation procedures within the last 8 weeks prior to screening visit,
* Upper gastrointestinal bleeding within 8 weeks prior to screening visit,
* Existing or intended pregnancy or breast-feeding.